Edition:
United States

CanniMed Therapeutics Inc (CMED.TO)

CMED.TO on Toronto Stock Exchange

19.71CAD
--
Change (% chg)

-- (--)
Prev Close
$19.71
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
77,249
52-wk High
$21.90
52-wk Low
$7.32

Chart for

About

CanniMed Therapeutics Inc is a Canada-based plant biopharmaceutical company. It is specialized in the production of pharmaceutical-grade cannabis and offers a range of pharmaceutical-grade cannabis products. In addition, the Company has a plant biotechnology research and product development program focused on the production of... (more)

Overall

Beta: --
Market Cap(Mil.): $446.84
Shares Outstanding(Mil.): 22.67
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 31.35 15.79
EPS (TTM): -- -- --
ROI: -- 15.11 12.01
ROE: -- 16.52 15.91

BRIEF-Aurora Cannabis intends to launch takeover bid for Cannimed Therapeutics

* Aurora Cannabis announces intention to launch takeover bid for Cannimed Therapeutics Inc.

Nov 20 2017

BRIEF-Cannimed to acquire UP Cannabis Inc

* Cannimed to acquire UP Cannabis Inc. (Newstrike Resources Ltd. – TSx-v:HIP) to create a premier global cannabis company

Nov 17 2017

BRIEF-Newstrike Resources discusses business combination with CanniMed

* Newstrike Resources says it previously entered exclusivity agreement, is in discussions with CanniMed regarding potential business combination transaction​

Nov 16 2017

BRIEF-CANNIMED ANNOUNCES INTENTION TO BUY NEWSTRIKE RESOURCES

* CANNIMED ACKNOWLEDGES AURORA PRESS RELEASE AND ANNOUNCES EXCLUSIVITY AGREEMENT AND INTENTION TO ACQUIRE NEWSTRIKE RESOURCES LTD.

Nov 15 2017

BRIEF-CanniMed Therapeutics, Avaria Health & Beauty signs letter of intent

* CanniMed Therapeutics - co, Avaria Health & Beauty signed letter of intent for distribution of medical cannabis products, clinical research Source text for Eikon: Further company coverage:

Oct 02 2017

BRIEF-Cannimed Therapeutics Q3 loss from cont ops $0.06 per share​

* Cannimed Therapeutics Inc. reports financial results for Q3 2017

Sep 11 2017

BRIEF-Cannimed Therapeutics says signed supply agreement with Akula Trading

* Says signed definitive supply agreement with Akula Trading Pty Ltd, a private South African Corporation​ Source text for Eikon: Further company coverage:

Aug 24 2017

BRIEF-Cannimed Therapeutics' Q2 loss per share $0.08

* Cannimed Therapeutics Inc reports financial results for Q2 2017

Jun 12 2017

Earnings vs. Estimates